Preparation and Evaluation of Valsartan Cubosomes
|
|
Author:
|
P.VISHNU , N.SADHANA, K.NAVEENBABU, M.SUNITHA REDDY, K.MAHESWARI
|
Abstract:
|
Cubosomes are discrete, sub-micron, nano-structured particles of the bi-continuous cubic liquid crystalline phase. The term "bicontinuous" refers to two distinct hydrophilic regions separated by the bi-layer. Bicontinuous cubic crystalline materials have been an active research topic because their structure lends itself well to controlled-release applications. Cubosomes are liquid crystalline nano-structures formed from the cubic phase of lipids, such as monooleate, or any other assembled lipid mixture and studied by means of high-resolution cryogenic transmission electron microscope (cryo-TEM)[1]. These are three dimensional structures resembling like honey-comb with distinct hydrophilic and hydrophobic regions. Cubosomes acts as carrier molecules for drugs, chemicals, peptides and proteins and protect them from degradation [2]. Valsartan blocks the actions of angiotensin II, which include constricting blood vessels and activating aldosterone, to reduce blood pressure. The drug binds to angiotensin type I receptors (AT1), working as an antagonist[3], which is a BCS class-II drug. In the present study Valsartan Cubosomes were prepared to increase the solubility as well as bioavailability. Six formulations(VF1-VF6) of Cubosomes were prepared by ultra-Sonication method by using different concentrations of glyceryl monooleate (GMO), Pluronic F127 and evaluated for Particle size, Drug release, Entrapment efficiency, Drug content among all VF4 formulations shown stable ,better drug release characters which is used for formulation of In-Situ gels. Seven In-Situ gel formulations(VFG1-VFG7) were prepared by using different concentrations of Carbopol, Sodium alginate, HPMC, Guar gum. Among all formulations VFG7 shown sustain release up to 12hrs with 98.9% drug release.
|
Keyword:
|
Cubosomes, GMO, Pluronic F127, Valsartan, TEM, Hypertension
|
EOI:
|
-
|
DOI:
|
https://doi.org/10.31838/ijpr/2020.12.04.069
|
Download:
|
Request For Article
|
|
|